Zacks Research Issues Pessimistic Outlook for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Equities research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a report released on Wednesday, March 5th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $2.42 for the year, down from their previous forecast of $2.52. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q1 2026 earnings at $0.48 EPS and FY2026 earnings at $2.55 EPS.

Other analysts also recently issued reports about the stock. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and an average target price of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Up 10.0 %

Shares of NYSE:TEVA traded up $1.47 during midday trading on Friday, reaching $16.14. 20,887,815 shares of the company were exchanged, compared to its average volume of 12,987,501. The stock has a fifty day simple moving average of $18.70 and a two-hundred day simple moving average of $18.35. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The firm has a market cap of $18.29 billion, a PE ratio of -11.13, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 273.5% in the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company's stock worth $82,000 after purchasing an additional 3,323 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Teva Pharmaceutical Industries by 73.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 465,032 shares of the company's stock valued at $8,380,000 after buying an additional 197,585 shares during the last quarter. Atria Investments Inc raised its position in shares of Teva Pharmaceutical Industries by 135.4% during the third quarter. Atria Investments Inc now owns 30,856 shares of the company's stock worth $556,000 after acquiring an additional 17,746 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its stake in shares of Teva Pharmaceutical Industries by 3.7% in the third quarter. State of New Jersey Common Pension Fund D now owns 473,509 shares of the company's stock worth $8,533,000 after acquiring an additional 16,700 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $60,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.